Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Merck
Fuji
Baxter
Boehringer Ingelheim
Cerilliant
Farmers Insurance
US Department of Justice
Teva
Dow

Generated: October 23, 2017

DrugPatentWatch Database Preview

SOMAVERT Drug Profile

« Back to Dashboard

What is the patent landscape for Somavert, and when can generic versions of Somavert launch?

Somavert is a drug marketed by Pharmacia And Upjohn and is included in one NDA. There is one patent protecting this drug.

This drug has fifty-four patent family members in fifteen countries and eight supplementary protection certificates in eight countries.

The generic ingredient in SOMAVERT is pegvisomant. One supplier is listed for this compound. Additional details are available on the pegvisomant profile page.

Summary for Tradename: SOMAVERT

US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list15
Drug Prices:see details
DailyMed Link:SOMAVERT at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-001Mar 25, 2003RXYesYes► Subscribe► SubscribeY ► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-004Jul 31, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-002Mar 25, 2003RXYesYes► Subscribe► SubscribeY ► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-003Mar 25, 2003RXYesYes► Subscribe► SubscribeY ► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-005Jul 31, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: SOMAVERT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-004Jul 31, 2014► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-003Mar 25, 2003► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-001Mar 25, 2003► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-002Mar 25, 2003► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-003Mar 25, 2003► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-003Mar 25, 2003► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-003Mar 25, 2003► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-004Jul 31, 2014► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-002Mar 25, 2003► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-003Mar 25, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: SOMAVERT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,451,561 Growth hormone variants► Subscribe
6,136,563 Human growth hormone variants comprising amino acid substitutions► Subscribe
5,534,617 Human growth hormone variants having greater affinity for human growth hormone receptor at site 1► Subscribe
5,854,026 Human growth hormone variant having enhanced affinity for human growth hormone receptor at site 1► Subscribe
6,143,523 Human growth hormone variants► Subscribe
6,013,478 Method for identifying active domains and amino acid residues in polypeptides and hormone variants► Subscribe
6,040,136 Enrichment method for variant proteins with altered binding properties► Subscribe
6,428,954 Method for identifying active domains and amino acid residues in polypeptides and hormone variants► Subscribe
5,834,250 Method for identifying active domains and amino acid residues in polypeptides and hormone variants► Subscribe
6,057,292 Method for inhibiting growth hormone action► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SOMAVERT

Country Document Number Estimated Expiration
European Patent Office1568771► Subscribe
Germany69635026► Subscribe
Germany851925► Subscribe
Canada2001774► Subscribe
Austria301196► Subscribe
World Intellectual Property Organization (WIPO)9711178► Subscribe
Japan3247940► Subscribe
Spain2113940► Subscribe
Hong Kong1012508► Subscribe
Canada2230492► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SOMAVERT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0043France► SubscribePRODUCT NAME: PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001-003 20021113
C029/2005Ireland► SubscribeSPC029/2005: 20061023, EXPIRES: 20171112
8Finland► Subscribe
2005 00043Denmark► Subscribe
0210Netherlands► Subscribe300210, 20160920, EXPIRES: 20171112
C/GB05/047United Kingdom► SubscribePRODUCT NAME: PEGVISOMANT, OPTIONALLY IN THE FORM OF A PEGYLATION VARIANT; REGISTRATION NO/DATE: EU/1/02/240/001 - 003 20021113
0851925/01Switzerland► SubscribeFORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH
204Luxembourg► Subscribe91204, EXPIRES: 20171113
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Teva
Queensland Health
Federal Trade Commission
Argus Health
Fish and Richardson
Julphar
Covington
Boehringer Ingelheim
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot